Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Patient-centred research is the core of MORU's activities. Geographically dispersed across 5 research units and 50 sites across Asia and Africa, our integrated, highly collaborative, flexible network lets MORU address global and regional health problems such as drug resistant infections, malaria and critical illness

Dr Bob Taylor with Dr Peter Olupot-Olupot conversing with his team at the training in Mbale, Uganda for the primaquine in African Children (PAC) study. © 2019 MORU. Photo by Prayoon Yentrakul
Dr Bob Taylor (left) with Dr Peter Olupot-Olupot (2nd left) and his team at the training in Mbale, Uganda for the primaquine in African Children (PAC) study. Led by MORU, PAC is assessing the safety of single low dose primaquine for blocking transmission in children with falciparum malaria and glucose-6-phosphate dehydrogenase deficiency. PAC's results will have a substantial impact on malaria elimination policies in Africa.